Document is current
Any future updates will be listed below
-
Authors
Campbell, Duncan J.
Coller, Jennifer M.
Gong, Fei Fei
McGrady, Michele
Boffa, Umberto
Shiel, Louise
Liew, Danny
Stewart, Simon
Owen, Alice J.
Krum, Henry
Reid, Christopher M.
Prior, David L.
- License Information
-
More Information
Article History
Received: 21 January 2021
Accepted: 23 March 2021
First Online: 26 April 2021
Declarations
:
: This study was approved by the Alfred Human Research Ethics Committee, conformed to the ethical standards of the Declaration of Helsinki, and written informed consent was obtained from all participants.
: Not applicable.
: Bupa Australia was involved in study design, recruitment of participants, and funding, but was not involved in data collection, analysis or interpretation, or writing of the article. Bupa Australia had no control or influence over the decision to submit the final manuscript for publication.U.B. was an employee of Bupa Australia. D.L. has received honoraria from Pfizer, Sanofi, Astra-Zeneca, Abbott, Bayer, MSD, GSK, Novartis and Nycomed. S.S. has received unrestricted educational grants from Schering Plough and Boehringer Ingelheim, and was Principal Investigator of the Novartis-sponsored Valsartan Intensified Primary Care Reduction of Blood Pressure (VIPER-BP) Study. H.K. received support from Novartis, Bristol-Myers Squibb, and Ardian/Medtronic. D.L.P. received payment from Johnson & Johnson, Bayer and Novartis for lectures. The remaining authors have no disclosures to report.
